Yu Rebecca Miao

This inventor holds 8 USPTO granted patents and 11 published patent applications and 5 EPO patents. Top assignees: Leland Stanford Junior University, Aravive Biologics, Inc., Akso Biopharmaceutical, Inc.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yu Rebecca Miao. Retrieved from https://idiyas.com/inventor/yu-rebecca-miao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 11)

% Patents Active = 75.0

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 39(Granted Patents)

Location History:

San Jose, CA (US) (2020)
Sunnyvale, CA (US) (2013 - 2021)
Stanford, CA (US) (2022)

Company Filing History:

8 out of 5,515

Leland Stanford Junior University

patents

4 out of 5

Aravive Biologics, Inc.

patents

1 out of 1

Akso Biopharmaceutical, Inc.

patent

where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11498955 - SPD-1 variant# FC fusion proteins (2022-11-15),

2. 11136563 - Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy (2021-10-05),

3. 10876176 - Antifibrotic activity of GAS6 inhibitor (2020-12-29),

4. 9879061 - Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis (2018-01-30),

5. 9822347 - Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy (2017-11-21),

6. 9266947 - Inhibition of AXL signaling in anti-metastatic therapy (2016-02-23),

7. 9074192 - Inhibition of AXL signaling in anti-metastatic therapy (2015-07-07),

8. 8618254 - Inhibition of AXL signaling in anti-metastatic therapy (2013-12-31),

Title: Innovations of Yu Rebecca Miao

Introduction

Yu Rebecca Miao is a prominent inventor based in San Jose, California. She has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic proteins. With a total of eight patents to her name, Miao's work has the potential to impact cancer treatment and other medical applications.

Latest Patents

Among her latest patents is the SPD-1 variant# FC fusion proteins, which focuses on novel sPD-1 variant—Fc fusion proteins. This invention aims to enhance therapeutic efficacy in treating various diseases. Another notable patent involves modified AXL peptides and their use in the inhibition of AXL signaling in anti-metastatic therapy. This invention provides compositions and methods for alleviating cancer in mammals by administering a pharmaceutical composition that inhibits the activity of AXL, MER, or Tyro3 protein activity.

Career Highlights

Yu Rebecca Miao has worked with esteemed institutions such as Leland Stanford Junior University and Aravive Biologics, Inc. Her career reflects a commitment to advancing medical science through innovative research and development.

Collaborations

Miao has collaborated with notable professionals in her field, including Amato J Giaccia and Mihalis S Kariolis. These collaborations have further enriched her research and contributed to her success as an inventor.

Conclusion

Yu Rebecca Miao's contributions to biotechnology and her innovative patents demonstrate her significant role in advancing medical treatments. Her work continues to inspire future developments in the field.

Profile summary based on public USPTO records.